Form 4: Cumberland Pharmaceuticals CEO and Chairman A.J. Kazimi Increases Stake Through Open Market Purchases
Insider Trading Report
Cumberland Pharmaceuticals' Chairman and CEO, A.J. Kazimi, has increased his direct beneficial ownership in the company by acquiring 160 shares of common stock through a series of open market purchases in May 2025.
Summary
- A.J. Kazimi, Chairman and CEO, and a 10% owner of Cumberland Pharmaceuticals Inc. (CPIX), acquired additional common stock.
- The purchases were made through a Rule 10b5-1 trading plan adopted on November 14, 2024.
- A total of 160 shares of common stock were acquired directly by Mr. Kazimi between May 1, 2025, and May 30, 2025.
- Individual transactions involved the acquisition of 8 shares per trade, across 21 separate dates.
- The purchase prices for these shares ranged from a low of $4.50 to a high of $5.68 per share.
- Following these transactions, A.J. Kazimi's direct beneficial ownership in Cumberland Pharmaceuticals Inc. stands at 5,699,260 shares of common stock.
Sentiment
Score: 7
Explanation: The sentiment is positive due to significant insider buying by the Chairman and CEO, indicating strong confidence in the company's future performance. While the number of shares acquired is small relative to total holdings, the consistent buying over multiple days under a 10b5-1 plan is a positive signal.
Positives
- The Chairman and CEO, A.J. Kazimi, increased his direct beneficial ownership, which can signal management confidence in the company's future prospects.
- The purchases were executed under a pre-arranged Rule 10b5-1 trading plan, indicating a systematic approach to increasing ownership.
Future Outlook
This Form 4 filing does not contain any forward-looking statements or guidance regarding the company's future outlook.
Industry Context
This Form 4 filing reports an insider transaction and does not provide broader industry context or trends. However, insider buying in the pharmaceutical sector can sometimes indicate management's positive view on upcoming drug approvals, pipeline developments, or market opportunities.
Related Party Transactions
- The reported transactions are open market purchases of common stock by A.J. Kazimi, who is the Chairman, CEO, and a 10% owner of Cumberland Pharmaceuticals, making these related party transactions.
Stakeholder Impact
- Shareholders may view the insider buying as a positive indicator of management's belief in the company's value, potentially boosting investor confidence.
- Employees might interpret the CEO's increased stake as a sign of stability and long-term commitment to the company's success.
Key Dates
| Date | Description |
|---|---|
| 2024-11-14 | Date Rule 10b5-1 trading plan was adopted by the reporting person. |
| 2025-05-01 | Earliest transaction date for common stock acquisition. |
| 2025-05-02 | Transaction date for common stock acquisition. |
| 2025-05-05 | Transaction date for common stock acquisition. |
| 2025-05-06 | Transaction date for common stock acquisition. |
| 2025-05-07 | Transaction date for common stock acquisition. |
| 2025-05-08 | Transaction date for common stock acquisition. |
| 2025-05-09 | Transaction date for common stock acquisition. |
| 2025-05-12 | Transaction date for common stock acquisition. |
| 2025-05-13 | Transaction date for common stock acquisition. |
| 2025-05-14 | Transaction date for common stock acquisition. |
| 2025-05-15 | Transaction date for common stock acquisition. |
| 2025-05-16 | Transaction date for common stock acquisition. |
| 2025-05-19 | Transaction date for common stock acquisition. |
| 2025-05-20 | Transaction date for common stock acquisition. |
| 2025-05-21 | Transaction date for common stock acquisition. |
| 2025-05-22 | Transaction date for common stock acquisition. |
| 2025-05-23 | Transaction date for common stock acquisition. |
| 2025-05-27 | Transaction date for common stock acquisition. |
| 2025-05-28 | Transaction date for common stock acquisition. |
| 2025-05-29 | Transaction date for common stock acquisition. |
| 2025-05-30 | Latest transaction date for common stock acquisition. |
| 2025-06-06 | Date of SEC Form 4 filing. |
Recommendation
buyKeywords
Cumberland Pharmaceuticals, CPIX, A.J. Kazimi, Insider Trading, Form 4, Stock Purchase, CEO, Chairman, 10b5-1 Plan, Pharmaceuticals
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.